NCT06501807View on ClinicalTrials.gov

BIOlogics in Severe Nasal POlyposis SurvEy.: a French Registry

NANot yet recruitingINTERVENTIONAL

Enrollment

900

Participants

Timeline

Start Date

September 2, 2024

Primary Completion Date

September 2, 2034

Study Completion Date

January 2, 2035

Conditions

Rhinosinusitis ChronicNasal Polyps

Interventions

DRUG

Biologic treatments available in Chronic Rhinosinusitis with Nasal Polyps (dupilumab, mepolizumab and benralizumab according to their marketing approval).

Drug prescription according to their marketing approval (subcutaneously, every month or every two weeks).

Trial Locations (1)

Unknown

CHU de Lille, Lille

All Listed Sponsors

lead

University Hospital, Lille

OTHER

NCT06501807 - BIOlogics in Severe Nasal POlyposis SurvEy.: a French Registry | Biotech Hunter | Biotech Hunter